急性重症溃疡性结肠炎试验:过去、现在与未来
该系统性综述评估了所有在因重症溃疡性结肠炎住院患者中进行的介入性随机对照试验,概述了从过去到现在的治疗疗效,并评估了研究人群、入选标准和研究设计等试验特征随时间的演变。综述还详细介绍了该领域正在进行的随机对照试验,并对未来临床试验项目的挑战及克服方法提出了展望,以帮助提供新的急性重症溃疡性结肠炎疗法。
要点
- 1955年可的松里程碑试验确立了药物疗效,并产生了首个疾病严重程度标准和临床试验终点。
- 20世纪90年代及世纪之交的试验确立了英夫利西单抗和环孢素的疗效,但此后药物开发进展甚微。
- 该综述评估了所有在住院重症溃疡性结肠炎患者中进行的介入性随机对照试验,并展望了未来试验挑战。
核心结论
- 自20世纪90年代及世纪之交确立英夫利西单抗和环孢素疗效以来,这一高风险人群的药物开发进展甚微。
研究设计与样本
- 系统性综述,评估所有在因重症溃疡性结肠炎住院患者中进行的介入性随机对照试验。
主要发现
- 1955年可的松里程碑试验确立了药物疗效,并产生了首个疾病严重程度标准和临床试验终点。
- 20世纪90年代及世纪之交的试验确立了英夫利西单抗和环孢素的疗效。
- 综述评估了试验特征随时间的演变,包括研究人群、入选标准和研究设计。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute severe ulcerative colitis (ASUC), characterised by bloody diarrhoea and systemic inflammation, is associated with a significant risk of colectomy and a small risk of mortality. The landmark trial of cortisone in 1955 was pivotal for two reasons: first, for establishing the efficacy of a drug that remains a first-line therapy today and, second, for producing the first set of disease severity criteria and clinical trial endpoints that shaped the subsequent ASUC trial landscape. Trials in the 1990s and at the turn of the millennium established the efficacy of infliximab and ciclosporin, but since then, there has been little progress in drug development for this high-risk population. This systematic review evaluates all interventional randomised controlled trials (RCTs) conducted in patients hospitalised with severe UC. It provides an overview of the efficacy of treatments from past to present and assesses the evolution of trial characteristics with respect to study populations, eligibility criteria and study designs over time. This review details ongoing RCTs in this field and provides a perspective on the challenges for future clinical trial programmes and how these can be overcome to help deliver novel ASUC therapies.
引用
- Honap S, Jairath V, Sands BE, et al. Acute severe ulcerative colitis trials: the past, the present and the future. Gut. 2024. PMID: 38834296. doi:10.1136/gutjnl-2024-332489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。